_version_ 1868266201736544257
author Chen, Xiaohui
Li, Rongna
Qiu, Yingkun
Lin, Fanhong
Chen, Shutong
Li, Xiaodan
Sun, Hui
Jiang, Guanmin
Fang, Hua
Qin, Jingbo
Fang, Meijuan
author_facet Chen, Xiaohui
Li, Rongna
Qiu, Yingkun
Lin, Fanhong
Chen, Shutong
Li, Xiaodan
Sun, Hui
Jiang, Guanmin
Fang, Hua
Qin, Jingbo
Fang, Meijuan
Chen, Xiaohui
Li, Rongna
Qiu, Yingkun
Lin, Fanhong
Chen, Shutong
Li, Xiaodan
Sun, Hui
Jiang, Guanmin
Fang, Hua
Qin, Jingbo
Fang, Meijuan
collection PubMed - marine biology
contents Design, synthesis, and biological evaluation of N-(2-amino-phenyl)-5-(4-aryl- pyrimidin-2-yl) amino)-1H-indole-2-carboxamide derivatives as novel inhibitors of CDK9 and class I HDACs for cancer treatment. Chen, Xiaohui Li, Rongna Qiu, Yingkun Lin, Fanhong Chen, Shutong Li, Xiaodan Sun, Hui Jiang, Guanmin Fang, Hua Qin, Jingbo Fang, Meijuan Humans Cyclin-Dependent Kinase 9 Histone Deacetylase Inhibitors Antineoplastic Agents Structure-Activity Relationship Drug Design Drug Screening Assays, Antitumor Cell Proliferation Molecular Structure Histone Deacetylases Indoles Dose-Response Relationship, Drug Animals Protein Kinase Inhibitors Mice Apoptosis Cell Line, Tumor Molecular Docking Simulation The mechanisms underlying transcriptional dysregulation in tumorigenesis have received considerable attention as promising therapeutic targets to combat human cancer. Cyclin-dependent kinase 9 (CDK9) and class I histone deacetylases (HDACs) are significant therapeutic targets due to their pivotal roles in the dysregulated transcriptional programs characteristic of many cancers. Furthermore, the combinatorial transcriptional therapy with CDK9 and class I HDAC inhibitors has been shown to have a synergistic anticancer effect. In this study, a series of novel N-(2-amino-phenyl)-5-(4-aryl-pyrimidin-2-yl) amino)-1H-indole-2-carboxamide derivatives were designed and synthesized as novel dual-functional inhibitors targeting CDK9 and HDAC signaling pathways for cancer treatment. Among the synthesized compounds, 13ea demonstrated potent anti-proliferative activities (IC
format Artículo científico
id pubmed_40383016
institution PubMed
language en
publishDate 2025
publisher Bioorganic chemistry
record_format pubmed
spellingShingle Design, synthesis, and biological evaluation of N-(2-amino-phenyl)-5-(4-aryl- pyrimidin-2-yl) amino)-1H-indole-2-carboxamide derivatives as novel inhibitors of CDK9 and class I HDACs for cancer treatment.
Chen, Xiaohui
Li, Rongna
Qiu, Yingkun
Lin, Fanhong
Chen, Shutong
Li, Xiaodan
Sun, Hui
Jiang, Guanmin
Fang, Hua
Qin, Jingbo
Fang, Meijuan
Humans
Cyclin-Dependent Kinase 9
Histone Deacetylase Inhibitors
Antineoplastic Agents
Structure-Activity Relationship
Drug Design
Drug Screening Assays, Antitumor
Cell Proliferation
Molecular Structure
Histone Deacetylases
Indoles
Dose-Response Relationship, Drug
Animals
Protein Kinase Inhibitors
Mice
Apoptosis
Cell Line, Tumor
Molecular Docking Simulation
Design, synthesis, and biological evaluation of N-(2-amino-phenyl)-5-(4-aryl- pyrimidin-2-yl) amino)-1H-indole-2-carboxamide derivatives as novel inhibitors of CDK9 and class I HDACs for cancer treatment. Chen, Xiaohui Li, Rongna Qiu, Yingkun Lin, Fanhong Chen, Shutong Li, Xiaodan Sun, Hui Jiang, Guanmin Fang, Hua Qin, Jingbo Fang, Meijuan Humans Cyclin-Dependent Kinase 9 Histone Deacetylase Inhibitors Antineoplastic Agents Structure-Activity Relationship Drug Design Drug Screening Assays, Antitumor Cell Proliferation Molecular Structure Histone Deacetylases Indoles Dose-Response Relationship, Drug Animals Protein Kinase Inhibitors Mice Apoptosis Cell Line, Tumor Molecular Docking Simulation The mechanisms underlying transcriptional dysregulation in tumorigenesis have received considerable attention as promising therapeutic targets to combat human cancer. Cyclin-dependent kinase 9 (CDK9) and class I histone deacetylases (HDACs) are significant therapeutic targets due to their pivotal roles in the dysregulated transcriptional programs characteristic of many cancers. Furthermore, the combinatorial transcriptional therapy with CDK9 and class I HDAC inhibitors has been shown to have a synergistic anticancer effect. In this study, a series of novel N-(2-amino-phenyl)-5-(4-aryl-pyrimidin-2-yl) amino)-1H-indole-2-carboxamide derivatives were designed and synthesized as novel dual-functional inhibitors targeting CDK9 and HDAC signaling pathways for cancer treatment. Among the synthesized compounds, 13ea demonstrated potent anti-proliferative activities (IC
title Design, synthesis, and biological evaluation of N-(2-amino-phenyl)-5-(4-aryl- pyrimidin-2-yl) amino)-1H-indole-2-carboxamide derivatives as novel inhibitors of CDK9 and class I HDACs for cancer treatment.
topic Humans
Cyclin-Dependent Kinase 9
Histone Deacetylase Inhibitors
Antineoplastic Agents
Structure-Activity Relationship
Drug Design
Drug Screening Assays, Antitumor
Cell Proliferation
Molecular Structure
Histone Deacetylases
Indoles
Dose-Response Relationship, Drug
Animals
Protein Kinase Inhibitors
Mice
Apoptosis
Cell Line, Tumor
Molecular Docking Simulation
url https://pubmed.ncbi.nlm.nih.gov/40383016/